Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases
Open Access
- 14 November 2018
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 24 (9_suppl) , 314S-322S
Abstract
The prevalence of neurocognitive deficits remains high in patients with stage 5 chronic kidney disease (CKD5D). Major contributors to such deficits include stroke, cervical carotid artery disease (CCAD), and intracranial atherosclerotic disease (ICAD). The risk of developing these dysfunctional vascular processes is facilitated by the chronic inflammation associated with renal failure. Plasma levels of 10 circulating biomarkers in patients with CKD5D (n = 78-90) were quantified using the sandwich enzyme linked immune sorbent assay method. Biomarkers for this study included kidney injury molecule-1, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), neutrophil gelatinase-associated lipocalin, interleukin-18, endothelin 1, calcifediol, parathyroid hormone, platelet-derived growth factor, microparticles-expressing tissue factor, and lipoprotein(a) (Lp(a)). Of the 90 patients with CKD5D, 30 had CCAD, 24 had ICAD, and 22 had stroke. Lp(a) level was significantly elevated in patients with CKD5D with comorbid ICAD compared to those without (125.70 ± 10.03 ng/mL vs 97.16 ± 5.97 ng/mL; P = .0065). NT-proBNP level was also significantly elevated in patients with CKD5D with comorbid stroke diagnosis compared to those without stroke history, once patients with a diagnosis of heart failure (HF) were excluded (14.84 ± 2.80 ng/mL vs 9.06 ± 1.27 ng/mL; P = .0283). Profiling levels of Lp(a) and NT-ProBNP could thus be useful in the risk stratification of ICAD and stroke, respectively, in the CKD5D population.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (T35HL120835)
This publication has 65 references indexed in Scilit:
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice GuidelineAnnals of Internal Medicine, 2013
- Racial-Ethnic Disparities in Stroke Care: The American ExperienceStroke, 2011
- Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohortAnnals of Neurology, 2010
- Lipid and Lipoprotein Metabolism in Chronic Kidney DiseaseJournal of Renal Nutrition, 2009
- Stroke in chronic kidney diseaseIndian Journal of Nephrology, 2009
- Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis?Clinical and Experimental Nephrology, 2008
- Kidney Function and Cognitive Impairment in US Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) StudyAmerican Journal of Kidney Diseases, 2008
- Kidney injury molecule–1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cellsJournal of Clinical Investigation, 2008
- Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: An Occult BurdenAdvances in Chronic Kidney Disease, 2008
- Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routineHeart, 2005